Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in three major healthcare investor conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 13), the Stifel 2024 Healthcare Conference (Nov 18), and the Jefferies London Healthcare Conference (Nov 20). Live audio webcasts and replays will be accessible through Spyre's investor events website.
Spyre Therapeutics (NASDAQ: SYRE), una compagnia biotech in fase clinica focalizzata sul trattamento della Malattia Infiammatoria Intestinale (IBD), ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario questo novembre. L'azienda presenterà alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim (13 novembre), alla Conferenza Sanitaria Stifel 2024 (18 novembre) e alla Conferenza Sanitaria di Jefferies a Londra (20 novembre). Saranno disponibili webcast audio in diretta e registrazioni sul sito degli eventi per investitori di Spyre.
Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en etapa clínica centrada en el tratamiento de la Enfermedad Inflamatoria Intestinal (IBD), ha anunciado su participación en tres importantes conferencias para inversores en el sector sanitario este noviembre. La empresa presentará en la Conferencia Inaugural de Innovación Sanitaria de Guggenheim (13 de noviembre), en la Conferencia de Salud Stifel 2024 (18 de noviembre) y en la Conferencia de Salud de Jefferies en Londres (20 de noviembre). Se podrán acceder a las transmisiones de audio en vivo y a las repeticiones a través del sitio web de eventos para inversores de Spyre.
Spyre Therapeutics (NASDAQ: SYRE), 염증성 장 질환(IBD) 치료에 집중하는 임상 단계의 생명공학 회사가 이번 11월 세 가지 주요 의료 투자자 컨퍼런스에 참가한다고 발표했습니다. 이 회사는 구겐하임의 첫 의료 혁신 컨퍼런스 (11월 13일), 스티펠 2024 의료 컨퍼런스 (11월 18일), 그리고 제퍼리스 런던 의료 컨퍼런스 (11월 20일)에서 발표할 예정입니다. Spyre의 투자자 이벤트 웹사이트를 통해 생중계 오디오 웹캐스트와 다시보기를 이용할 수 있습니다.
Spyre Therapeutics (NASDAQ: SYRE), une entreprise de biotechnologie en phase clinique spécialisée dans le traitement de la Maladie Inflammatoire de l'Intestin (IBD), a annoncé sa participation à trois grandes conférences pour investisseurs dans le secteur de la santé ce mois de novembre. L'entreprise présentera lors de la Conférence Inaugurale sur l'Innovation Sanitaire de Guggenheim (13 novembre), de la Conférence Healthcare Stifel 2024 (18 novembre) et de la Conférence Healthcare de Jefferies à Londres (20 novembre). Des webcasts audio en direct et des rediffusions seront accessibles via le site web des événements pour investisseurs de Spyre.
Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Entzündlichen Darmerkrankungen (IBD) spezialisiert hat, hat seine Teilnahme an drei wichtigen Gesundheitsinvestoren-Konferenzen im November bekannt gegeben. Das Unternehmen wird auf der Ersten Gesundheitsinnovationskonferenz von Guggenheim (13. November), der Stifel Gesundheitskonferenz 2024 (18. November) und der Jefferies Gesundheitskonferenz in London (20. November) präsentieren. Live-Audio-Webcasts und Wiederholungen sind über die Investorenevents-Website von Spyre zugänglich.
- None.
- None.
Event: Guggenheim's Inaugural Healthcare Innovation Conference
Date: Wednesday, November 13, 2024
Time: 2:30pm ET
Event: Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 1:15 pm ET
Event: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 10:30 am GMT
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-november-investor-conferences-302291439.html
SOURCE Spyre Therapeutics, Inc.
FAQ
What investor conferences will Spyre Therapeutics (SYRE) attend in November 2024?
When is Spyre Therapeutics (SYRE) presenting at the Guggenheim Healthcare Conference 2024?
How can investors access Spyre Therapeutics (SYRE) conference presentations?
What is the main therapeutic focus of Spyre Therapeutics (SYRE)?
